Cantor Fitzgerald on Friday downgraded Gossamer Bio (GOSS) to Neutral from Overweight without a price target The firm cites the negative Phase 3 readout for PROSERA and an unclear regulatory path forward for seralutinib in pulmonary arterial hypertension for the downgrade. It is challenging to have conviction in whether Gossamer has a strong case for a path to commercialization, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOSS:
- Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
- Bracing for Stagflation? These 2 Stocks Offer Mouth-Watering Upside
- Gossamer Bio’s Seralutinib Future in Doubt After PROSERA Miss in PAH Raises FDA, Funding and Viability Risks
- Gossamer Bio reports Q4 EPS (21c), consensus (20c)
- Stagflation Risk Is Back — These 3 Stocks Can Help Defend Your Portfolio